Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the recipient of a significant decline in short interest during the month of January. As of January 15th, there was short interest totalling 31,500 shares, a decline of 58.7% from the December 31st total of 76,200 shares. Based on an average daily volume of 787,700 shares, the short-interest ratio is currently 0.0 days.
Astellas Pharma Stock Performance
Shares of OTCMKTS ALPMY traded down $0.21 during midday trading on Friday, hitting $9.68. 94,828 shares of the stock traded hands, compared to its average volume of 266,996. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.86 and a current ratio of 1.10. Astellas Pharma has a one year low of $9.05 and a one year high of $13.14. The firm has a market capitalization of $17.52 billion, a P/E ratio of 46.10 and a beta of 0.34. The firm has a 50-day moving average of $9.88 and a two-hundred day moving average of $10.97.
Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last announced its earnings results on Wednesday, October 30th. The company reported $0.13 earnings per share (EPS) for the quarter. The business had revenue of $3.11 billion for the quarter. Astellas Pharma had a return on equity of 10.40% and a net margin of 3.26%. On average, equities analysts forecast that Astellas Pharma will post 0.58 EPS for the current fiscal year.
About Astellas Pharma
(
Get Free Report)
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
Featured Articles
Before you consider Astellas Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astellas Pharma wasn't on the list.
While Astellas Pharma currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
